Primary Laparoscopic Surgery Does Not Affect the Prognosis of Early-Stage Ovarian Clear Cell Cancer

Yin, Sheng; Gao, Wen; Shi, Peipei; Xi, Meili; Tang, Wenqi; Zhang, Jiarong

doi:10.2147/cmar.s321173

Cited by 7 publications

(6 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Over recent years, the minimally invasive approach has revolutionized surgical care [1]. Accumulating evidence highlighted that minimally invasive surgery correlated with better perioperative outcomes than open surgery [2,3]. In comparison to open surgery, minimally-invasive surgery is associated with lower postoperative pain, recovery time, hospital stays, and marked improvements in cosmetic outcome and overall cost-effectiveness either in benign or malignant disease.…”

Section: Introductionmentioning

confidence: 99%

Practice patterns and 90-day treatment-related morbidity in early-stage cervical cancer

Bogani

Donato²,

Scambia³

et al. 2022

Gynecologic Oncology

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

Practice patterns and 90-day treatment-related morbidity in early-stage cervical cancer

Bogani

Donato²,

Scambia³

et al. 2022

Gynecologic Oncology

View full text Add to dashboard Cite

“…However, the oncologic safety needed to be further demonstrated [ 21 ]. However, the retrospective data from Yin et al proposed that laparoscopic surgery did not affect the PFS and OS of early-stage OCCC [ 22 ]. So a well-designed randomized controlled trial was warranted.…”

Section: Discussionmentioning

confidence: 99%

Impact of the number of cycles of platinum-based chemotherapy for early stage ovarian clear cell carcinoma on survival: a retrospective study

2023

BMC Women's Health

View full text Add to dashboard Cite

Background Ovarian clear cell carcinoma (OCCC) is a unique subtype of ovarian epithelial ovarian cancer. The number of chemotherapy cycles for early-stage patients is still debated. This study aimed to evaluate whether at least 4 cycles of adjuvant platinum-based chemotherapy have better prognostic value than 1–3 cycles in early-stage OCCC. Methods We retrospectively retrieved data from 102 patients with stage I-IIA OCCC between 2008 and 2017. All patients underwent complete surgical staging followed by adjuvant platinum-based chemotherapy. Kaplan-Meier curves and Multivariate Cox analysis were performed to estimate 5-year overall survival (OS) and progression-free (PFS) according to the number of chemotherapy cycles. Results Among stage I-IIA disease, twenty (19.6%) patients received 1–3 cycles, and eighty-two (80.4%) patients received at least 4 cycles of adjuvant chemotherapy. Univariate analysis revealed that the patients in 1-3cycles group had not significantly improved 5-year OS and PFS than those in the ≥ 4 cycles group (5-year OS: hazard ratio [HR] 1.21; 95% confidence interval [CI] 0.25– 5.78, p = 0.1), and 5-year PFS: HR 0.79; 95% CI 0.26– 2.34, p = 0.1). In the multivariate analysis, there was no impact of 1–3 versus ≥ 4 cycles of chemotherapy on 5-year OS (HR 1.21, 95% CI 0.25–3.89, p = 0.8) or 5-year PFS (HR 0.94, 95% CI 0.32–2.71, p = 0.9). The potential independent risk factors associated with 5-year OS and PFS included the surgery approach and FIGO stage. Conclusion The number of cycles of platinum-based chemotherapy could not be associated with a survival benefit for patients with early-stage OCCC.

show abstract

“…According to reports, the mortality rate of ovarian cancer ranks first among gynecological malignancies. Most cases originate from the ovarian epithelium and during the course of the disease, local infiltration and distant metastasis are common[ 1 ]. Ovarian cancer accounts for 2.5% of female malignancies, and the 5-year survival rate for early-stage ovarian cancer is as high as 93%.…”

Section: Introductionmentioning

confidence: 99%

Efficacy and safety of minimally invasive laparoscopic surgery under general anesthesia for ovarian cancer

Qin,

Chen,

Liu

et al. 2024

World J Clin Cases

View full text Add to dashboard Cite

BACKGROUND Ovarian cancer is one of the most common malignant tumors in female reproductive system in the world, and the choice of its treatment is very important for the survival rate and prognosis of patients. Traditional open surgery is the main treatment for ovarian cancer, but it has the disadvantages of big trauma and slow recovery. With the continuous development of minimally invasive technology, minimally invasive laparoscopic surgery under general anesthesia has been gradually applied to the treatment of ovarian cancer because of its advantages of less trauma and quick recovery. However, the efficacy and safety of minimally invasive laparoscopic surgery under general anesthesia in the treatment of ovarian cancer are still controversial. AIM To explore the efficacy and safety of general anesthesia minimally invasive surgery in the treatment of ovarian cancer. METHODS The clinical data of 90 patients with early ovarian cancer in our hospital were analyzed retrospectively. According to the different surgical treatment methods, patients were divided into study group and control group (45 cases in each group). The study group received minimally invasive laparoscopic surgery under general anesthesia for ovarian cancer, while the control group received traditional open surgery for ovarian cancer. The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30), clinical efficacy and safety of the two groups were compared. RESULTS The intraoperative blood loss, length of hospital stay, postoperative gas evacuation time, and postoperative EORTC QLQ-C30 score of the study group were significantly better than those of the control group (P < 0.05). The incidence of postoperative complications in the study group was significantly lower than in the control group (P < 0.05). The two groups had no significant differences in the preoperative adrenocorticotropic hormone (ACTH), androstenedione (AD), cortisol (Cor), cluster of differentiation 3 positive (CD3+), and cluster of differentiation 4 positive (CD4+) indexes (P > 0.05). In contrast, postoperatively, the study group's ACTH, AD, and Cor indexes were lower, and the CD3+ and CD4+ indexes were higher than those in the control group (P < 0.05). CONCLUSION Minimally invasive laparoscopic surgery under general anesthesia in patients with early ovarian cancer can significantly improve the efficacy and safety, improve the short-term prognosis and quality of life of patients, and is worth popularizing.

show abstract

Primary Laparoscopic Surgery Does Not Affect the Prognosis of Early-Stage Ovarian Clear Cell Cancer

Cited by 7 publications

References 29 publications

Practice patterns and 90-day treatment-related morbidity in early-stage cervical cancer

Practice patterns and 90-day treatment-related morbidity in early-stage cervical cancer

Impact of the number of cycles of platinum-based chemotherapy for early stage ovarian clear cell carcinoma on survival: a retrospective study

Efficacy and safety of minimally invasive laparoscopic surgery under general anesthesia for ovarian cancer

Contact Info

Product

Resources

About